sars cov 2 2019 ncov spike s1 mfc recombinant protein covid 19 spike s1 research  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Name:
    SARS CoV 2 2019 nCoV Spike S1 mFc Recombinant Protein COVID 19 Spike S1 Research
    Description:
    A DNA sequence encoding the SARS CoV 2 2019 nCoV spike protein S1 Subunit YP 009724390 1 Val16 Arg685 was expressed with the Fc region of mouse IgG1 at the C terminus
    Catalog Number:
    40591-V05H1
    Price:
    None
    Category:
    recombinant protein
    Product Aliases:
    coronavirus spike Protein 2019-nCoV, cov spike Protein 2019-nCoV, ncov RBD Protein 2019-nCoV, ncov s1 Protein 2019-nCoV, ncov s2 Protein 2019-nCoV, ncov spike Protein 2019-nCoV, NCP-CoV RBD Protein 2019-nCoV, NCP-CoV s1 Protein 2019-nCoV, NCP-CoV s2 Protein 2019-nCoV, NCP-CoV Spike Protein 2019-nCoV, novel coronavirus RBD Protein 2019-nCoV, novel coronavirus s1 Protein 2019-nCoV, novel coronavirus s2 Protein 2019-nCoV, novel coronavirus spike Protein 2019-nCoV, RBD Protein 2019-nCoV, S1 Protein 2019-nCoV, S2 Protein 2019-nCoV, Spike RBD Protein 2019-nCoV
    Host:
    HEK293 Cells
    Buy from Supplier


    Structured Review

    Sino Biological sars cov 2 2019 ncov spike s1 mfc recombinant protein covid 19 spike s1 research
    A DNA sequence encoding the SARS CoV 2 2019 nCoV spike protein S1 Subunit YP 009724390 1 Val16 Arg685 was expressed with the Fc region of mouse IgG1 at the C terminus
    https://www.bioz.com/result/sars cov 2 2019 ncov spike s1 mfc recombinant protein covid 19 spike s1 research/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike s1 mfc recombinant protein covid 19 spike s1 research - by Bioz Stars, 2021-06
    97/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
    Article Snippet: Antibody binding and competition with receptor ACE2The binding affinity of antibodies to S protein was analyzed by ELISA. .. The 384-well plate (Corning, Catalog #3700) was coated overnight at 4 °C with PBS containing 30 μL 20 nM of the SARS-CoV-2 Spike S1+S2 ECD, his Tag protein (Sino Biological, Catalog #40589-V08B1), or SARS-CoV-2 Spike RBD-mFc recombinant protein (Sino Biological, Catalog #40592-V05H) or S1-mFc (Sino Biological, Catalog #40591-V05H1). ..

    Article Title: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
    Article Snippet: .. Convalescent COVID-19 patient antibody titers against SARS-CoV-2 S proteinsThe 384-well plates were coated overnight at 4 °C with PBS containing 1 µg/mL of SARS-CoV-2 Spike RBD-mFc recombinant protein (Sino Biological, Catalog #40592-V05H) or full-length S-his (Sino Biological, Catalog #40589-V08B1) or S1-mFc (Sino Biological, Catalog #40591-V05H1) or S1-his (Kactus, Catalog #COV-VM4S1). ..

    Binding Assay:

    Article Title: Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2
    Article Snippet: Flow cytometryTransfected cells were sorted for HDR+ by staining for Strep-Tactin-APC 1:100 (IBA lifesciences, Cat: 6-5010-001) and anti-hIgG AF488 1:100 (Jackson ImmunoResearch, Cat: 109-545-003). .. Enriched cells were then selected for antigen binding by incubating with SARS-CoV-2 S1-mFc 1:75 (Sinobiological, Cat: 40591-V05H1), S2-mFc 1:75 (Sinobiological, Cat: 40590-V05B) on ice for 20 min, followed by a single wash and a secondary staining with anti-mFc IgG1: PE and/or APC [clone RMG1-1] at 1:100 (Biolegend, Cat: 406608/406610). .. After enrichment for S1, cells were also tested for binding to SARS-CoV-2 RBD-mFc 1:375 (Sinobiological, Cat: 40592-V05H), and the same secondary staining.

    Staining:

    Article Title: Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2
    Article Snippet: Flow cytometryTransfected cells were sorted for HDR+ by staining for Strep-Tactin-APC 1:100 (IBA lifesciences, Cat: 6-5010-001) and anti-hIgG AF488 1:100 (Jackson ImmunoResearch, Cat: 109-545-003). .. Enriched cells were then selected for antigen binding by incubating with SARS-CoV-2 S1-mFc 1:75 (Sinobiological, Cat: 40591-V05H1), S2-mFc 1:75 (Sinobiological, Cat: 40590-V05B) on ice for 20 min, followed by a single wash and a secondary staining with anti-mFc IgG1: PE and/or APC [clone RMG1-1] at 1:100 (Biolegend, Cat: 406608/406610). .. After enrichment for S1, cells were also tested for binding to SARS-CoV-2 RBD-mFc 1:375 (Sinobiological, Cat: 40592-V05H), and the same secondary staining.

    Incubation:

    Article Title: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
    Article Snippet: Vero E6 cell line (ATCC, CRL-1587) was validated by CoBIOER ( http://www.cobioer.com/ ) and tested negative for mycoplasma contamination. .. Then, 10 nM SARS-CoV-2 Spike S1, mFc tag protein (Sino Biological, Catalog #40591-V05H1) was incubated with a serial dilution of purified antibodies at room temperature for 1 h and then added to Vero E6 cells (105 cells per well). .. Rabbit anti-mouse IgG Fc-AF647 (Jackson ImmunoResearch, Catalog #315-606-046, 1:800 dilution) was then added before final wash and data acquisition with a Cytoflex flow cytometer (Beckman) and data analysis using FlowJo software (version 10.6.0).

    Serial Dilution:

    Article Title: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
    Article Snippet: Vero E6 cell line (ATCC, CRL-1587) was validated by CoBIOER ( http://www.cobioer.com/ ) and tested negative for mycoplasma contamination. .. Then, 10 nM SARS-CoV-2 Spike S1, mFc tag protein (Sino Biological, Catalog #40591-V05H1) was incubated with a serial dilution of purified antibodies at room temperature for 1 h and then added to Vero E6 cells (105 cells per well). .. Rabbit anti-mouse IgG Fc-AF647 (Jackson ImmunoResearch, Catalog #315-606-046, 1:800 dilution) was then added before final wash and data acquisition with a Cytoflex flow cytometer (Beckman) and data analysis using FlowJo software (version 10.6.0).

    Purification:

    Article Title: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
    Article Snippet: Vero E6 cell line (ATCC, CRL-1587) was validated by CoBIOER ( http://www.cobioer.com/ ) and tested negative for mycoplasma contamination. .. Then, 10 nM SARS-CoV-2 Spike S1, mFc tag protein (Sino Biological, Catalog #40591-V05H1) was incubated with a serial dilution of purified antibodies at room temperature for 1 h and then added to Vero E6 cells (105 cells per well). .. Rabbit anti-mouse IgG Fc-AF647 (Jackson ImmunoResearch, Catalog #315-606-046, 1:800 dilution) was then added before final wash and data acquisition with a Cytoflex flow cytometer (Beckman) and data analysis using FlowJo software (version 10.6.0).

    Article Title: The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
    Article Snippet: The reaction was developed by TMB substrate and the optical densities at 450 nm were determined (Metertech960 enzyme marker with 450 nm wavelength). .. Laboratory preparation of the antibody of SARS-CoV-2 spike-1 (S1) protein Mice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein (Extended Data Figure 5).

    Mouse Assay:

    Article Title: The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
    Article Snippet: The reaction was developed by TMB substrate and the optical densities at 450 nm were determined (Metertech960 enzyme marker with 450 nm wavelength). .. Laboratory preparation of the antibody of SARS-CoV-2 spike-1 (S1) protein Mice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein (Extended Data Figure 5).

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Sino Biological anti s2
    N-glycan modification of SARS-CoV-2 pseudovirus abolishes entry into 293T/ACE2 cells. A . Pseudovirus expressing VSVG envelope protein, Spike-WT and Spike-mutant were produced in wild-type, [O] − and [N] − 293T cells. All 9 viruses were applied at equal titer to stable 293T/ACE2. B - C . O-glycan truncation of Spike partially reduced viral entry. N-glycan truncation abolished viral entry. In order to combine data from multiple viral preparations and independent runs in a single plot, all data were normalized by setting DsRed signal produced by virus generated in wild-type 293T to 10,000 normalized MFI or 100% normalized DsRed positive value. D . Viral titration study performed with Spike-mutant virus shows complete loss of viral infection over a wide range. E . Western blot of Spike protein using <t>anti-S2</t> Ab shows reduced proteolysis of Spike-mut compared to Spike-WT. The full Spike protein and free S2-subunit resulting from S1-S2 cleavage is indicated. Molecular mass is reduced in [N] − 293T products due to truncation of glycan biosynthesis. F . Anti-FLAG Ab binds the C-terminus of Spike-mutant. Spike produced in [N] − 293Ts is almost fully proteolyzed during viral production (red arrowhead). * P
    Anti S2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti s2/product/Sino Biological
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti s2 - by Bioz Stars, 2021-06
    99/100 stars
      Buy from Supplier

    96
    Sino Biological sars cov 2 spike antibody
    Flow cytometric analysis of total T cell (CD4 + ) populations producing IL-2 on mouse splenocyte upon <t>SARS-CoV-2</t> S protein stimulation. Cells were gated in an orderly manner, like singlets were gated, followed by lymphocytes, CD45 + , CD45 + CD4 + and CD45 + CD4 + IL2 + (A, B, C) 3 control panels where 0.26%, 0.26% and 0.13% CD45 + CD4 + IL2 + cells were identified respectively, (D, E, F) 3 treatment panels where 0.73%, 0.69% and 0.63% CD45 + CD4 + IL2 + cells were identified respectively.
    Sars Cov 2 Spike Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 spike antibody/product/Sino Biological
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 spike antibody - by Bioz Stars, 2021-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    N-glycan modification of SARS-CoV-2 pseudovirus abolishes entry into 293T/ACE2 cells. A . Pseudovirus expressing VSVG envelope protein, Spike-WT and Spike-mutant were produced in wild-type, [O] − and [N] − 293T cells. All 9 viruses were applied at equal titer to stable 293T/ACE2. B - C . O-glycan truncation of Spike partially reduced viral entry. N-glycan truncation abolished viral entry. In order to combine data from multiple viral preparations and independent runs in a single plot, all data were normalized by setting DsRed signal produced by virus generated in wild-type 293T to 10,000 normalized MFI or 100% normalized DsRed positive value. D . Viral titration study performed with Spike-mutant virus shows complete loss of viral infection over a wide range. E . Western blot of Spike protein using anti-S2 Ab shows reduced proteolysis of Spike-mut compared to Spike-WT. The full Spike protein and free S2-subunit resulting from S1-S2 cleavage is indicated. Molecular mass is reduced in [N] − 293T products due to truncation of glycan biosynthesis. F . Anti-FLAG Ab binds the C-terminus of Spike-mutant. Spike produced in [N] − 293Ts is almost fully proteolyzed during viral production (red arrowhead). * P

    Journal: bioRxiv

    Article Title: Inhibition of SARS-CoV-2 viral entry in vitro upon blocking N- and O-glycan elaboration

    doi: 10.1101/2020.10.15.339838

    Figure Lengend Snippet: N-glycan modification of SARS-CoV-2 pseudovirus abolishes entry into 293T/ACE2 cells. A . Pseudovirus expressing VSVG envelope protein, Spike-WT and Spike-mutant were produced in wild-type, [O] − and [N] − 293T cells. All 9 viruses were applied at equal titer to stable 293T/ACE2. B - C . O-glycan truncation of Spike partially reduced viral entry. N-glycan truncation abolished viral entry. In order to combine data from multiple viral preparations and independent runs in a single plot, all data were normalized by setting DsRed signal produced by virus generated in wild-type 293T to 10,000 normalized MFI or 100% normalized DsRed positive value. D . Viral titration study performed with Spike-mutant virus shows complete loss of viral infection over a wide range. E . Western blot of Spike protein using anti-S2 Ab shows reduced proteolysis of Spike-mut compared to Spike-WT. The full Spike protein and free S2-subunit resulting from S1-S2 cleavage is indicated. Molecular mass is reduced in [N] − 293T products due to truncation of glycan biosynthesis. F . Anti-FLAG Ab binds the C-terminus of Spike-mutant. Spike produced in [N] − 293Ts is almost fully proteolyzed during viral production (red arrowhead). * P

    Article Snippet: Identity of expressed protein and also viral Spike was determined using western blotting with anti-Fc (Jackson), anti-RBD (Sino Biologicals), anti-S2 (Sino Biologicals) and anti-ACE2 (R & D Systems) pAbs.

    Techniques: Modification, Expressing, Mutagenesis, Produced, Generated, Titration, Infection, Western Blot

    Illustrations of the interactions involving SARS-CoV-2 RBD. ( A ) Interactions between the RBD portion of SARS-CoV-2 and the ACE2 receptor on the host cell can be impaired via neutralizing antibodies. ( B ) Interactions between HiBiT-RBD and LgBiT lead to the generation of bioluminescence signal after substrate digestion.

    Journal: Nanomaterials

    Article Title: A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion

    doi: 10.3390/nano11030807

    Figure Lengend Snippet: Illustrations of the interactions involving SARS-CoV-2 RBD. ( A ) Interactions between the RBD portion of SARS-CoV-2 and the ACE2 receptor on the host cell can be impaired via neutralizing antibodies. ( B ) Interactions between HiBiT-RBD and LgBiT lead to the generation of bioluminescence signal after substrate digestion.

    Article Snippet: High Accuracy of the HiBiT-RBD Reporter for SARS-CoV-2 Neutralizing Antibodies with Considerable AffinityThe HiBiT-RBD reporter was initially validated by testing two different commercial SARS-CoV-2 neutralizing antibodies, SinoBiological 40592 and ActiveMotif 1414, in comparison to control IgG ( A,B).

    Techniques:

    The detection of antibodies using the HiBiT-RBD serological assay. ( A ) Illustration of the NanoBiT serological assay. ( B ) High signal intensity and detection of the SARS-CoV-2 neutralizing antibodies compared to no signal for the control antibody. ( C ) Presence of signal in all positive patient cases and no false-positive results in negative samples. This experiment performed in the 96 well plates which showed the compatibility of the assay for high through put screening.

    Journal: Nanomaterials

    Article Title: A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion

    doi: 10.3390/nano11030807

    Figure Lengend Snippet: The detection of antibodies using the HiBiT-RBD serological assay. ( A ) Illustration of the NanoBiT serological assay. ( B ) High signal intensity and detection of the SARS-CoV-2 neutralizing antibodies compared to no signal for the control antibody. ( C ) Presence of signal in all positive patient cases and no false-positive results in negative samples. This experiment performed in the 96 well plates which showed the compatibility of the assay for high through put screening.

    Article Snippet: High Accuracy of the HiBiT-RBD Reporter for SARS-CoV-2 Neutralizing Antibodies with Considerable AffinityThe HiBiT-RBD reporter was initially validated by testing two different commercial SARS-CoV-2 neutralizing antibodies, SinoBiological 40592 and ActiveMotif 1414, in comparison to control IgG ( A,B).

    Techniques: Serologic Assay

    N-glycan modification of SARS-CoV-2 pseudovirus abolishes entry into 293T/ACE2 cells. ( A ) Pseudovirus expressing VSVG envelope protein, Spike-WT and Spike-mutant were produced in wild-type, [O] - and [N] - 293 T cells. All nine viruses were applied at equal titer to stable 293T/ACE2. ( B–C ) O-glycan truncation of Spike partially reduced viral entry. N-glycan truncation abolished viral entry. In order to combine data from multiple viral preparations and independent runs in a single plot, all data were normalized by setting DsRed signal produced by virus generated in wild-type 293T to 10,000 normalized MFI or 100% normalized DsRed positive value. ( D ) Viral titration study performed with Spike-mutant virus shows complete loss of viral infection over a wide range. ( E ) Western blot of Spike protein using anti-S2 Ab shows reduced proteolysis of Spike-mut compared to Spike-WT. The full Spike protein and free S2-subunit resulting from S1-S2 cleavage is indicated. Molecular mass is reduced in [N] - 293T products due to truncation of glycan biosynthesis. ( F ) Anti-FLAG Ab binds the C-terminus of Spike-mutant. Spike produced in [N] - 293Ts is almost fully proteolyzed during viral production (red arrowhead). *p

    Journal: eLife

    Article Title: Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration

    doi: 10.7554/eLife.61552

    Figure Lengend Snippet: N-glycan modification of SARS-CoV-2 pseudovirus abolishes entry into 293T/ACE2 cells. ( A ) Pseudovirus expressing VSVG envelope protein, Spike-WT and Spike-mutant were produced in wild-type, [O] - and [N] - 293 T cells. All nine viruses were applied at equal titer to stable 293T/ACE2. ( B–C ) O-glycan truncation of Spike partially reduced viral entry. N-glycan truncation abolished viral entry. In order to combine data from multiple viral preparations and independent runs in a single plot, all data were normalized by setting DsRed signal produced by virus generated in wild-type 293T to 10,000 normalized MFI or 100% normalized DsRed positive value. ( D ) Viral titration study performed with Spike-mutant virus shows complete loss of viral infection over a wide range. ( E ) Western blot of Spike protein using anti-S2 Ab shows reduced proteolysis of Spike-mut compared to Spike-WT. The full Spike protein and free S2-subunit resulting from S1-S2 cleavage is indicated. Molecular mass is reduced in [N] - 293T products due to truncation of glycan biosynthesis. ( F ) Anti-FLAG Ab binds the C-terminus of Spike-mutant. Spike produced in [N] - 293Ts is almost fully proteolyzed during viral production (red arrowhead). *p

    Article Snippet: Identity of expressed protein and also viral Spike was determined using western blotting with anti-Fc (Jackson), anti-RBD (Sino Biologicals), anti-S2 (Sino Biologicals) and anti-ACE2 (R and D Systems) pAbs.

    Techniques: Modification, Expressing, Mutagenesis, Produced, Generated, Titration, Infection, Western Blot

    Flow cytometric analysis of total T cell (CD4 + ) populations producing IL-2 on mouse splenocyte upon SARS-CoV-2 S protein stimulation. Cells were gated in an orderly manner, like singlets were gated, followed by lymphocytes, CD45 + , CD45 + CD4 + and CD45 + CD4 + IL2 + (A, B, C) 3 control panels where 0.26%, 0.26% and 0.13% CD45 + CD4 + IL2 + cells were identified respectively, (D, E, F) 3 treatment panels where 0.73%, 0.69% and 0.63% CD45 + CD4 + IL2 + cells were identified respectively.

    Journal: bioRxiv

    Article Title: BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

    doi: 10.1101/2020.09.29.319061

    Figure Lengend Snippet: Flow cytometric analysis of total T cell (CD4 + ) populations producing IL-2 on mouse splenocyte upon SARS-CoV-2 S protein stimulation. Cells were gated in an orderly manner, like singlets were gated, followed by lymphocytes, CD45 + , CD45 + CD4 + and CD45 + CD4 + IL2 + (A, B, C) 3 control panels where 0.26%, 0.26% and 0.13% CD45 + CD4 + IL2 + cells were identified respectively, (D, E, F) 3 treatment panels where 0.73%, 0.69% and 0.63% CD45 + CD4 + IL2 + cells were identified respectively.

    Article Snippet: The plate was washed for 3 times then incubated with mouse sera and SARS-CoV-2 Spike antibody (Sino Biological, China) for 2 hours at 37 °C.

    Techniques:

    Flow cytometric analysis of total T cell (CD4 + ) populations producing TFN alpha on mouse splenocyte upon SARS-CoV-2 S protein stimulation. Cells were gated in an orderly manner, like singlets were gated, followed by lymphocytes, CD45 + , CD45 + CD4 + and CD45 + CD4 + TFNalpha + (A, B, C) 3 control panels where 0.48%, 0.43% and 0.37% CD45 + CD4 + TFNalpha + cells were identified respectively, (D, E, F) 3 treatment panels where 0.99%, 0.95% and 0.81% CD45 + CD4 + TFNalpha + cells were identified respectively.

    Journal: bioRxiv

    Article Title: BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

    doi: 10.1101/2020.09.29.319061

    Figure Lengend Snippet: Flow cytometric analysis of total T cell (CD4 + ) populations producing TFN alpha on mouse splenocyte upon SARS-CoV-2 S protein stimulation. Cells were gated in an orderly manner, like singlets were gated, followed by lymphocytes, CD45 + , CD45 + CD4 + and CD45 + CD4 + TFNalpha + (A, B, C) 3 control panels where 0.48%, 0.43% and 0.37% CD45 + CD4 + TFNalpha + cells were identified respectively, (D, E, F) 3 treatment panels where 0.99%, 0.95% and 0.81% CD45 + CD4 + TFNalpha + cells were identified respectively.

    Article Snippet: The plate was washed for 3 times then incubated with mouse sera and SARS-CoV-2 Spike antibody (Sino Biological, China) for 2 hours at 37 °C.

    Techniques:

    SARS-CoV-2 S protein mapping via LC-MS/MS.

    Journal: bioRxiv

    Article Title: BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

    doi: 10.1101/2020.09.29.319061

    Figure Lengend Snippet: SARS-CoV-2 S protein mapping via LC-MS/MS.

    Article Snippet: The plate was washed for 3 times then incubated with mouse sera and SARS-CoV-2 Spike antibody (Sino Biological, China) for 2 hours at 37 °C.

    Techniques: Liquid Chromatography with Mass Spectroscopy

    SARS-CoV-2 S protein mapping via ExPASy PeptideMass.

    Journal: bioRxiv

    Article Title: BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

    doi: 10.1101/2020.09.29.319061

    Figure Lengend Snippet: SARS-CoV-2 S protein mapping via ExPASy PeptideMass.

    Article Snippet: The plate was washed for 3 times then incubated with mouse sera and SARS-CoV-2 Spike antibody (Sino Biological, China) for 2 hours at 37 °C.

    Techniques:

    Target gene selection and modification; (A) Sequence alignment of SARS-CoV-2 surface glycoprotein, where D614 and G614 variants are visible, (B) hydrophilicity and hydrophobicity analysis of amino acid 611-620, where D614D is shown, (C) hydrophilicity and hydrophobicity analysis of amino acid 611-620, where D614G is shown (D) target sequence 3D model, (E) 3D model of amino acid 589-639; white arrow indicates D614D, (F) 3D model of amino acid 589-639; white arrow indicates D614G.

    Journal: bioRxiv

    Article Title: BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

    doi: 10.1101/2020.09.29.319061

    Figure Lengend Snippet: Target gene selection and modification; (A) Sequence alignment of SARS-CoV-2 surface glycoprotein, where D614 and G614 variants are visible, (B) hydrophilicity and hydrophobicity analysis of amino acid 611-620, where D614D is shown, (C) hydrophilicity and hydrophobicity analysis of amino acid 611-620, where D614G is shown (D) target sequence 3D model, (E) 3D model of amino acid 589-639; white arrow indicates D614D, (F) 3D model of amino acid 589-639; white arrow indicates D614G.

    Article Snippet: The plate was washed for 3 times then incubated with mouse sera and SARS-CoV-2 Spike antibody (Sino Biological, China) for 2 hours at 37 °C.

    Techniques: Selection, Modification, Sequencing

    In-vitro neutralization assay. (A) Image of Green fluorescence protein (GFP) expression after adeno-based SARS-CoV-2 pseudovirus neutralization assay from 2 -4 sample dilution, (B) correlation between SARS-CoV-2 antibody from mice sera and intensity of GFP in different experimental group. For treatment group with the decrease of the antibody concentration, the intensity of GFP expression increased, which indicated the inhibition of SARS-Cov-2 pseudovirus into ACE2 overexpressed HEK293 cell (ACE2-HEK293 cell), (C) adeno-based SARS-CoV-2 pseudovirus neutralization percentage at different sample dilution, (D) HIV-1 based SARS-CoV-2 pseudovirus copy number analysis by qPCR; all the samples were compared by one-way ANNOVA method, ****= p-value

    Journal: bioRxiv

    Article Title: BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

    doi: 10.1101/2020.09.29.319061

    Figure Lengend Snippet: In-vitro neutralization assay. (A) Image of Green fluorescence protein (GFP) expression after adeno-based SARS-CoV-2 pseudovirus neutralization assay from 2 -4 sample dilution, (B) correlation between SARS-CoV-2 antibody from mice sera and intensity of GFP in different experimental group. For treatment group with the decrease of the antibody concentration, the intensity of GFP expression increased, which indicated the inhibition of SARS-Cov-2 pseudovirus into ACE2 overexpressed HEK293 cell (ACE2-HEK293 cell), (C) adeno-based SARS-CoV-2 pseudovirus neutralization percentage at different sample dilution, (D) HIV-1 based SARS-CoV-2 pseudovirus copy number analysis by qPCR; all the samples were compared by one-way ANNOVA method, ****= p-value

    Article Snippet: The plate was washed for 3 times then incubated with mouse sera and SARS-CoV-2 Spike antibody (Sino Biological, China) for 2 hours at 37 °C.

    Techniques: In Vitro, Neutralization, Fluorescence, Expressing, Mouse Assay, Concentration Assay, Inhibition, Real-time Polymerase Chain Reaction

    Flow cytometric analysis of total T cell (CD4 + ) populations producing IL-6 on mouse splenocyte upon SARS-CoV-2 S protein stimulation. Cells were gated in an orderly manner, like singlets were gated, followed by lymphocytes, CD45 + , CD45 + CD4 + and CD45 + CD4 + IL6 + (A, B, C) 3 control panels where 0.32%, 0.27% and 0.22% CD45 + CD4 + IL6 + cells were identified respectively, (D, E, F) 3 treatment panels where 0.47%, 0.39% and 0.34% CD45 + CD4 + IL6 + cells were identified respectively.

    Journal: bioRxiv

    Article Title: BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

    doi: 10.1101/2020.09.29.319061

    Figure Lengend Snippet: Flow cytometric analysis of total T cell (CD4 + ) populations producing IL-6 on mouse splenocyte upon SARS-CoV-2 S protein stimulation. Cells were gated in an orderly manner, like singlets were gated, followed by lymphocytes, CD45 + , CD45 + CD4 + and CD45 + CD4 + IL6 + (A, B, C) 3 control panels where 0.32%, 0.27% and 0.22% CD45 + CD4 + IL6 + cells were identified respectively, (D, E, F) 3 treatment panels where 0.47%, 0.39% and 0.34% CD45 + CD4 + IL6 + cells were identified respectively.

    Article Snippet: The plate was washed for 3 times then incubated with mouse sera and SARS-CoV-2 Spike antibody (Sino Biological, China) for 2 hours at 37 °C.

    Techniques: